

IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
02325	YUNKANG GROUP	2022/05/11	2022/05/17	2022/05/18

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit <u>www.cfsg.com.hk</u> or contact our account executives or customer service officers

Subscription Details via CASH Securities

Offer Period	2022/05/05-2022/05/11			
Closing Time for Margin Application	N/A			
Subscription Fee	N/A			
Days For Margin Financing	N/A			
Indicative Interest Rate	N/A			
*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.				

Yunkang Group Limited (2325.HK)

Share Offer Highlights	
Total Number of Offer Shares:	138,188,000 Shares(comprising113,188,500new Shares and 24,999,500 Sale Shares, and subject to the Over-allotment Option)
- Number of Public Offer Shares:	13,819,000 Shares (subject to adjustment)
- Number of Placing Shares:	124,369,000 Shares (comprising99,369,500 new Shares and 24,999,500 Sale Shares, and subject to adjustment and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 7.89 per Share
2020 Historical P/E ratio:	10.72X
Sponsor:	CMB INTERNATIONAL, SPDB INTERNATIONAL
Company Overview	

Company Overview

This company is a medical operation service provider in China offering a full suite of diagnostic testing services for medical institutions with a market share of 3.7% in China's medical operation service market in terms of revenue in 2020, according to Frost & Sullivan. Medical operation services primarily relate to diagnostic testing services provided to medical institutions which can be divided into diagnostic outsourcing services and diagnostic testing services for medical institution alliances (醫 聯體)(i). According to Frost & Sullivan, China's medical operation service market is expected to grow from RMB30,694.9 million in 2020 to RMB47,946.1 million in 2025 at a CAGR of 9.3%. To a lesser extent, it also provides diagnostic testing services to non-medical institutions in China via an outpatient clinic.

For the year ended December 31, 2019, 2020 and 2021, the Company's net profits(losses) were RMB (30.96) mn , RMB 255.33 mn and RMB 380.93 mn respectively.

Source		
IPO Prospectus		
Contact Us		
Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
Wealth Management Centre:	1001B, 10/F, Tower 535 Jaffe Road Causeway Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building,683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen 2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-755) 2216 5888 (86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026



Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.